Sexual Health / side effects and safety / Last reviewed 2026-06-02

PT-141 Side Effects: Safety Signals and Warnings

PT-141 safety concerns are compound-specific. The main listed side effects are Nausea (40%), Flushing, and Headache. The main warning signals are Contraindicated in uncontrolled hypertension, May cause transient BP increase, and Limit to 8 doses per month.

Read the full PT-141 guide Browse answer pages

Direct Answer

PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in premenopausal women (Vyleesi), providing a regulatory anchor for sexual health research. Phase 3 data in women is solid; male sexual dysfunction data is earlier-stage. For melanocortin-pathway sexual health research, this is the best-evidenced starting point.

Evidence grade
Level A
Research status
FDA Approved
Category
Sexual Health
Best for
Hypoactive sexual desire disorder (women), sexual dysfunction research, melanocortin pathway

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

FDA-approved as Vyleesi for HSDD in premenopausal women (2019). Prescription required. Available by auto-injector. Not approved for male sexual dysfunction. Also available as a research peptide.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesFemale Sexual Desire (Level A), Nausea (Level A), and Male Erectile Function (Level B)
Primary citation count2
Last reviewed2026-06-02

Related Guides

How to Cite This Page

ExaminePeptides. "PT-141 Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/pt-141-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.